H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 28.36 CNY -5.5% Market Closed
Market Cap: 26B CNY
Have any thoughts about
Hubei Jumpcan Pharmaceutical Co Ltd?
Write Note

Hubei Jumpcan Pharmaceutical Co Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hubei Jumpcan Pharmaceutical Co Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Research & Development
-ÂĄ457.5m
CAGR 3-Years
-20%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-ÂĄ2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-ÂĄ232.3m
CAGR 3-Years
-31%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-ÂĄ5.8B
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-ÂĄ339.2m
CAGR 3-Years
-19%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Research & Development
-ÂĄ712.5m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Jumpcan Pharmaceutical Co Ltd
Glance View

Market Cap
26.1B CNY
Industry
Pharmaceuticals

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs. The company is headquartered in Taizhou, Jiangsu and currently employs 6,632 full-time employees. The company went IPO on 2001-08-22. The firm's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The firm mainly distributes its products within domestic markets.

Intrinsic Value
46.9 CNY
Undervaluation 40%
Intrinsic Value
Price
H

See Also

What is Hubei Jumpcan Pharmaceutical Co Ltd's Research & Development?
Research & Development
-457.5m CNY

Based on the financial report for Jun 30, 2024, Hubei Jumpcan Pharmaceutical Co Ltd's Research & Development amounts to -457.5m CNY.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-24%

Over the last year, the Research & Development growth was 23%. The average annual Research & Development growth rates for Hubei Jumpcan Pharmaceutical Co Ltd have been -20% over the past three years , -24% over the past five years .

Back to Top